Kyoto Semiconductor Announces Two UV Sensors for Deep UV Sensing Applications
Kyoto Semiconductor Co., Ltd. (President and CEO Yoshihisa Shinya, Head office: Fushimi-ku, Kyoto city), a leading optical device solution manufacturer with world-class technologies and Japanese quality, has announced two products of GaN*1 UV sensor; "KPDU086SU27-H11Q and KPDU086SU31-H11Q".
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230204005014/en/
Kyoto Semiconductor KPDU086SU27/KPDU086SU31 (Photo: Business Wire)
The UV sensors "KPDU086SU27-H11Q" and "KPDU086SU31-H11Q" were developed with the aim of achieving higher sensitivity than conventional Si*2 type UV sensors to meet the needs of the deep UV*3 sensing market.
Since conventional Si-type UV sensors detect a wide range of wavelengths, it is common to apply a filter to limit the sensitivity to the UV wavelength range. The amount of light was attenuated by passing through the filter.
The newly developed KPDU086SU27-H11Q and KPDU086SU31-H11Q use GaN to enable direct light reception at the light receiving part of the sensor without using a filter as GaN has sensitivity to a specific wavelength range of ultraviolet light. It is now possible to obtain approximately three times as high sensitivity as Si-type UV sensors. *4
In addition, the products have sensitivity in the wavelength range limited to UV-B*5 and UV-C*6, which are in high demand among ultraviolet rays.
The new products can be used to monitor the ultraviolet light intensity of germicidal lamps in food factories, medical institutions, and water purification-related institutions, and to monitor the light intensity of ozone detection light sources.
The mass production of the GaN UV sensors "KPDU086SU27-H11Q and KPDU086SU31-H11Q" are scheduled to start on April 28, 2023.
For more information
https://www.kyosemi.co.jp/en/products/kpdu086su27-h11q/
https://www.kyosemi.co.jp/en/products/kpdu086su31-h11q/
*1 GaN: Gallium nitride a type of semiconductor
*2 Si: Silicon, a type of semiconductor
*3 Deep ultraviolet rays: UV rays in the emission wavelength range of λ = 200-300 nm. UV-B and UV-C are said to be deep UV rays.
*4 Comparison between KPDU086SU27-H11Q and our Si UV sensor KPDU400F-2
https://www.kyosemi.co.jp/products/kpdu400f-2/
*5 UV-B: Ultraviolet rays in the emission wavelength range of λ = 280 to 315 nm. Sensitivity wavelength range of KPDU086SU31-H11Q
*6 UV-C: Ultraviolet rays in the emission wavelength range of λ = 100 to 280 nm. Sensitivity wavelength range of KPDU086SU27-H11Q
About Kyoto Semiconductor
Kyoto Semiconductor was established in 1980 in Kyoto as a dedicated manufacturer of optical semiconductors. The semiconductors manufactured offer superlative performance and precision, suited for use in optical transmission. They are manufactured end-to-end, including pre- and post-processing, and together with Kyoto Semiconductor’s unique packaging technology, at our location in Japan and made available to customers around the world. Kyoto Semiconductor leads the industry with world-standard technologies for optical device solutions based on Japanese quality and attention to production detail.
Company Website: https://www.kyosemi.co.jp/
*Product names, company names, and organization names mentioned in this press release are trademarks or registered trademarks of their respective companies.
*All contents of this press release are as of the date of publication and subject to change without notice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230204005014/en/
Contact information
Media Relations, Kyoto Semiconductor Co., Ltd.
Email: Media_relation@kyosemi.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom